The hereditary spastic paraplegias (HSPs) refer to a group of neurodegenerative disorders, characterized by upper motor neuron degeneration leading to progressive spasticity and weakness of the lower limbs. This group of diseases is both clinically and genetically heterogenous, with several separate loci having been mapped. SPG35 is a recently described subtype of spastic paraplegia. Clinically, SPG35 is a severe form of the paraplegia, following a progressive course, and is associated with intellectual disability. Radiologically, the disease shows features of leukodystrophy.

There are no specific treatments to prevent HSP. Management consists of symptomatic treatment and regular physical therapy to strengthen muscles.

SPG35 has been found to be caused due to mutations in the FA2H (Fatty Acid 2 Hydroxylase) gene. It is not clear how defects in this gene could play a role in the development of SPG35. However, it is likely that abnormal hydroxylation of myelin galactocerebroside lipid components could be involved.